The estimated Net Worth of Peter S Klein is at least 1.17 百万$ dollars as of 6 August 2024. Mr. Klein owns over 9,196 units of Denali Therapeutics Inc stock worth over 767,149$ and over the last 14 years he sold DNLI stock worth over 0$. In addition, he makes 405,076$ as Independent Director at Denali Therapeutics Inc.
Peter has made over 23 trades of the Denali Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 9,196 units of DNLI stock worth 249,028$ on 6 August 2024.
The largest trade he's ever made was exercising 14,060 units of Denali Therapeutics Inc stock on 25 July 2023 worth over 380,745$. On average, Peter trades about 1,707 units every 58 days since 2010. As of 6 August 2024 he still owns at least 28,329 units of Denali Therapeutics Inc stock.
You can see the complete history of Mr. Klein stock trades at the bottom of the page.
Peter S. Klein serves as Independent Director of the Company. Mr. Klein served as Chief Financial Officer of William Morris Endeavor Entertainment, LLC (“WME”), a marketing firm, from January 2014 to June 2014. Prior to joining WME, Mr. Klein spent over 11 years at Microsoft Corporation, including serving as Chief Financial Officer from November 2009 until May 2013. Mr. Klein currently serves on the board of directors of F5 Networks Inc., a software company. Mr. Klein holds a B.A. in history from Yale University and an M.B.A. from the University of Washington.
As the Independent Director of Denali Therapeutics Inc, the total compensation of Peter Klein at Denali Therapeutics Inc is 405,076$. There are 10 executives at Denali Therapeutics Inc getting paid more, with Ryan Watts having the highest compensation of 4,978,610$.
Peter Klein is 57, he's been the Independent Director of Denali Therapeutics Inc since 2018. There are 7 older and 12 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.
Peter's mailing address filed with the SEC is C/O F5, INC., 801 5TH AVENUE, SEATTLE, WA, 98104.
Over the last 7 years, insiders at Denali Therapeutics Inc have traded over 438,930,443$ worth of Denali Therapeutics Inc stock and bought 275,000 units worth 4,950,000$ . The most active insiders traders include Llc Fmr、Douglas Kakdl, L.P.Crestlin...、Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,606,006$. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth 77,000$.
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Denali Therapeutics Inc executives and other stock owners filed with the SEC include: